## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

MAR Washington, DC 20231

Sir:

Transmitted herewith for filing is the PATENT APPLICATION of:

Inventor(s): Kenneth William Batchelor; Stephen Vernon Frye;

George F. Dorsey, Jr.; Robert A. Mook, Jr.

## Title: ANDROSTENONE DERIVATIVE

- 1. This is an application for an original invention, which is a continuation-inpart (CIP).
- 2. The new application being transmitted claims the benefit of prior International Application which designated the US and was filed 16 September 1994 as of PCT/US94/10530.
- The oath or declaration executed by inventors

  X is attached.
  will follow (an unsigned oath and Power of Attorney is attached.)

  4. Enclosed are -0- sheets of drawings.
- 5. The inventorship for all the claims in this application are:

\_\_\_\_\_ the same \_\_\_\_\_ the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,

\_\_\_\_ is submitted
\_\_X will be submitted

6. An assignment of the invention to Glaxo, Inc., Research Triangle Park, North Carolina

\_\_\_X\_is attached with separate cover letter and fee authority.\_\_\_\_will follow

- 7. A Certified copy of application was filed in PCT/US94/10530 filed 16 September 1994 from which priority is claimed.
- 8. The filing fees have been calculated as shown below:

<u>For</u>	No. Filed	No. Extra	Rate	<u>Fee</u>
Basic Fee				\$730
Total Claims	24 -20	4	x 22	= \$ 88
Indep Claims	3 - 3	0	× 76	= \$
Multiple Dependence	y Claims		+ 240	=
			TOTAL	\$ 818

If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

9. The composition is hereby authorized to charge payment of the following feet to be posit Account No. 07-1392. A duplicate copy of this sheet is enclosed. Please charge as follows:

XX Filing Fee

\$818.00

TOTAL \$ 818.00

10.	The	Commissioner	is	hereby	authorized	to	charge	payment	of	the
	follov	ving additional	fee	s during	the penden	су с	of this ap	plication of	or Ci	edit
	verpayment to	De	posit Ac	count No. 0	7-1:	392:				

a. X Any patent application processing fees under 37 CFR 1.17.

b. \_\_\_\_ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance pursuant to 37 CFR 1.311(b).

c. X Any filing fees under 37 CFR 1.16 for presentation of extra claims.

- 11. Address all correspondence to <u>Charles E. Dadswell</u>, Glaxo Inc., Five Moore Drive, Research Triangle Park, North Carolina 27709.
- 12. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: March 16, 1995

Glaxo Inc.

Research Triangle Park, North Carolina 27709 Charles E. Dadswell
Attorney for Applicant(s)

Registration No. 35,851

Telephone No: (919) 990-6983

CERTIFICATE OF MAILING (37 CFR 1.10)

Express Mail No. TB494703044 US sent 1995
I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as express mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: 16 March 1995

Rosalie Germano

	0/0-2			
Jac	organion by	reference of ad	ded pages:	
Mr.	Plus	Added Pages F	For New Application Transm	ittal Where
N	_ / \		rnational Application	
10 '	16		••	
PA 3	995 Relate Back	c35 USC 120		
1			y inserting before the first lin	ne the
	sentence:	"This is a	, mooning before the mooning	
		ation-in-part		
		ng application		
	•	•	n <u>PCT/US94/10530</u> filed on	16
		• •	h designated the US."	10
	September	1334 and winc	in designated the OS.	
14.	Poloto Paol	25 USC 120	Priority Claim for Prior Appli	aation
14.			Priority Claim for Prior Appli	
	•	* *	olication designating the US,	identified in
			ns priority as follows:	A become a series
			Filed: 17 September 1993 filed on	
	country	appl. no.	med on	status
	The cortifie	d agay bag bag	n filed 10 Nevember 1004 :	_
			n filed 10 November 1994 i	
	internation	al Application P	<u>CT/US94/10530</u> filed on <u>16</u>	<u>Sept 1994</u> .
4 -		- 04-4	have Danasia of Dulay Applicat	\ Ol=:
15.		-	here Benefit of Prior Appln(s	a) Claimed
		same		
			An explanation, including t	-
	various cla		the last claimed invention v	vas made,
		is submitted		
	>	will be subm	nitted	

This transmittal ends with this page.